Fintel reports that on March 7, 2025, Scotiabank initiated coverage of Avidity Biosciences (NasdaqGM:RNA) with a Sector ...

Antisense oligonucleotide (ASO) technology has accelerated drug discovery in the last few decades with several ASO-based ...

More generic drug prices decreased than increased in January, while nearly 1,000 brand-name drugs saw their prices increase ...

Merck KGaA CEO Belén Garijo says Trump's China tariffs impact manageable due to regionalized supply chains; company reports 2 ...

The global gene therapy market is projected to grow from $8.85 billion in 2024 to $36.55 billion by 2032, at a CAGR of 19.4%.

"In people with lupus nephritis, Gazyva/Gazyvaro demonstrated a complete renal response benefit, a meaningful clinical ...

Dosing underway in INLIGHT trial of WVE-007 in obesity with clinical data expected in 2H 2025; enrollment complete in first single dose cohort Multi-dosing ongoing in 200 mg cohort of RestorAATion-2 ...

Dosing underway in INLIGHT trial of WVE-007 in obesity with clinical data expected in 2H 2025; enrollment complete in first single dose ...

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies ...

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies ...

Net sales down 10.0% to €911.9 million, driven by lower volumes for Sanofi and the suspension of production at Brindisi, only ...

A new article in the journal Nucleic Acid Therapeutics addresses the recognition by the U.S. Food and Drug Administration ...